Method and system for analyzing cell subpopulations and functional characteristics of lung cancer brain metastasis organoids

By performing single-cell transcriptomic analysis on organoids from lung cancer brain metastases, we have solved the analytical challenges of single-cell heterogeneity and drug sensitivity in lung cancer brain metastases. This enables precise description of cell subpopulations and assessment of drug sensitivity, supporting personalized treatment plans for precision medicine.

WO2026232659A1PCT designated stage Publication Date: 2026-11-12SHANGHAI PULMONARY HOSPITAL (SHANGHAI OCCUPATIONAL DISEASE PREVENTION & TREATMENT HOSPITAL)
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/099675
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-07
Filing Date
2025-06-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There is a lack of analytical strategies for the heterogeneity of single-cell tumor cells in organoids, especially in lung cancer brain metastasis studies where it is difficult to obtain fresh tissue. Existing technologies cannot effectively describe the heterogeneity of tumor cells and the sensitivity of tumor cells to drugs after radiotherapy.

Method used

This invention provides a method and system for analyzing cell subpopulations and functional characteristics of organoids from lung cancer brain metastases, including data quality control, batch effect removal, cell clustering, inferred copy number variation, pseudo-time series analysis, and functional enrichment analysis. It also provides personalized analysis of organoids using single-cell transcriptomics technology to identify cell subpopulations and drug sensitivity.

Benefits of technology

This study enabled precise analysis of various cell subpopulations in lung cancer brain metastases, revealing the heterogeneity of tumor cells and their drug sensitivity after radiotherapy, thus providing support for the study of the mechanisms of lung cancer brain metastases and precision medicine.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2025099675_12112026_PF_FP_ABST
    Figure CN2025099675_12112026_PF_FP_ABST
Patent Text Reader

Abstract

Provided are a method and a system for analyzing cell subpopulations and functional characteristics of lung cancer brain metastasis organoids. Through a series of steps including data quality control, batch effect removal, cell clustering, copy number variation inference, pseudotime analysis, functional enrichment analysis, and drug sensitivity analysis before and after radiotherapy, individualized analysis is performed on single-cell transcriptome sequencing data obtained after organoid culture, thereby characterizing the heterogeneity of tumor cells and the sensitivity of the tumor cells to drugs after radiotherapy. The method can accurately analyze the characteristics of various cell subpopulations in lung cancer brain metastasis organoids and the roles thereof in the tumor microenvironment, thereby providing strong support for mechanism research and precision medicine of lung cancer brain metastasis.
Need to check novelty before this filing date? Find Prior Art

Description

A method and system for analyzing organoid cell subpopulations and functional characteristics in lung cancer brain metastases.

[0001] Cross-referencing

[0002] This application incorporates Chinese Patent Application No. 202510578011.6, filed on May 7, 2025, entitled "A Method and System for Analyzing Subpopulations and Functional Characteristics of Organoid Cells in Lung Cancer Brain Metastases," which is incorporated herein by reference in its entirety. Technical Field

[0003] This invention relates to the field of single-cell transcriptomics analysis technology, specifically to a method and system for analyzing the subpopulations and functional characteristics of organoid cells from lung cancer brain metastases. Background Technology

[0004] Organoids are models derived from the body's own tissues or stem cells, formed through in vitro 3D culture that possess the original tissue and organ structures. Organoids are highly similar to their source tissues in terms of tissue structure, cell type, and function, and have become important tools in disease models, drug efficacy studies, and precision medicine. Single-cell sequencing technology can obtain information at the individual cell level, effectively solving the problem of cellular heterogeneity that traditional population-based sequencing technologies have failed to reveal. This technology elevates the precision of research from the population-based cell level to the single-cell level, greatly promoting a deeper understanding of cellular heterogeneity and life activities.

[0005] However, research on lung cancer brain metastases is limited by sample availability, making it difficult to obtain fresh tissue. Currently, there is a lack of analytical strategies targeting the heterogeneity of single-cell tumor cells in organoids. This system, based on single-cell transcriptomics technology and combined with the characteristics of organoids, proposes a standardized analytical workflow for quality control, dimensionality reduction clustering, cluster analysis, and metabolic function enrichment analysis of single-cell data from lung cancer brain metastasis organoids. Summary of the Invention

[0006] The purpose of this invention is to provide a method and system for analyzing the subpopulations and functional characteristics of organoid cells in lung cancer brain metastases. The aim is to describe the heterogeneity of tumor cells and the sensitivity of tumor cells to drugs after radiotherapy by performing personalized analysis on single-cell transcriptome sequencing data after organoid culture.

[0007] To achieve the above objectives, the present invention provides, in one aspect, a method for analyzing the subpopulations and functional characteristics of organoid cells in lung cancer brain metastases, comprising:

[0008] Step S100: Data quality control. Perform quality control on the single-cell RNA sequencing data of organoids to remove low-quality data and ensure data reliability.

[0009] Step S200: Remove batch effects. Use a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency.

[0010] Step S300: Cell segmentation. Through dimensionality reduction and cluster analysis, cells are divided into different subpopulations, revealing their heterogeneity and diversity within the tumor microenvironment.

[0011] Step S400, inferring copy number variations: By analyzing copy number variations in single-cell data, inferring genomic instability and possible carcinogenic features of cells;

[0012] Step S500: Using pseudo-time series analysis, reconstruct the cell development or transformation process to explore changes in cell fate during lung cancer brain metastasis;

[0013] Step S600, functional enrichment analysis, identifies key pathways and molecular markers associated with lung cancer brain metastasis by functional annotation of different cell subpopulations;

[0014] Step S700: Drug sensitivity analysis before and after radiotherapy. This analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, providing a basis for individualized treatment plans.

[0015] Furthermore, in step S100, single-cell transcriptome data is read, and the overall situation of single-cell transcriptome data is checked in the R environment. Double cells are removed using the doubletFinder package, and samples with a mitochondrial ratio greater than 25% and a red blood cell ratio greater than 5% are screened out.

[0016] Furthermore, in step S200, the Harmony or Seurat algorithm is used to screen for highly variable genes and remove batch effects.

[0017] Furthermore, in step S300, cluster analysis is performed using PCA to separate 25 cell subpopulations, which are then visualized using UMAP. Subsequently, the expression of epithelial cell markers is combined, and tumor cells in organoids are inferred using the inferCNV method.

[0018] Furthermore, in step S300, after tumor cell identification, the cells are reclassified into four subpopulations based on markers of different cell subpopulations, including: low copy number tumor cell population, stem cell-like tumor cell population, stromal-like tumor cell population, and neutrophil-like tumor cell population, and the proportion of each subpopulation in different samples is calculated.

[0019] Furthermore, in step S400, the monocle3 package is used to infer the differentiation trajectory of cells, and it is found that stem cell-like tumor cell populations differentiate into neutrophil-like and stromal-like tumor cell populations in multiple ways. At the same time, low copy number tumor cell populations have lower differentiation characteristics. The cytoTRACE2 package is used to further infer the differentiation potential of the four subpopulations.

[0020] Furthermore, in step S500, the metabolic characteristics of each cell subpopulation are assessed using the scMetabolism package and visualized using a dot plot, showing that low copy number tumor cells have active multiple metabolic pathways.

[0021] Furthermore, the feature is that, in step S600, the pseudobulk package is used to compare differentially expressed genes in tumor cells before and after radiotherapy, identifying significantly upregulated genes. High expression of KRT17 and RAET1L was found to be associated with poor prognosis in patients with lung adenocarcinoma. Functional enrichment analysis based on differentially upregulated genes mainly involves biological processes such as humoral immunity and lymphocyte chemotaxis. KEGG analysis showed that related pathways include cytokine-receptor interactions, lipid metabolism, and atherosclerosis, while GSEA analysis showed statistically significant differences in drug metabolism pathways such as cytochrome P450 and phenylalanine metabolism.

[0022] Furthermore, in step S700, the oncoPredic package is used to predict the sensitivity of tumor cells to different drugs before and after radiotherapy, including the significant difference in IC50 values ​​of the lung cancer chemotherapy drug docetaxel.

[0023] On the other hand, the present invention also provides an analysis system for organoid cell subpopulations and functional characteristics in lung cancer brain metastases, comprising:

[0024] Data quality control module 1 performs quality control on organoid single-cell RNA sequencing data, removing low-quality data and ensuring data reliability;

[0025] Batch Effect Removal Module 2 employs a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency.

[0026] Cell clustering module 3, through dimensionality reduction and cluster analysis, divides cells into different subpopulations, revealing their heterogeneity and diversity within the tumor microenvironment.

[0027] The copy number variation inference module 4 infers genomic instability and possible carcinogenic features of cells by analyzing copy number variations in single-cell data.

[0028] Using the pseudo-time series analysis module 5, we reconstructed the cell development or transformation process and explored the changes in cell fate during lung cancer brain metastasis.

[0029] Functional enrichment analysis module 6 identifies key pathways and molecular markers associated with lung cancer brain metastasis by performing functional annotation on different cell subpopulations.

[0030] Module 7, which analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, provides a basis for individualized treatment plans.

[0031] This invention has the following technological advancements and beneficial effects:

[0032] This invention provides a method and system for analyzing cell subpopulations and functional characteristics of organoids from lung cancer brain metastases. Through a series of steps including data quality control, batch effect removal, cell clustering, inferred copy number variation, pseudo-temporal analysis, functional enrichment analysis, and pre- and post-radiotherapy drug sensitivity analysis, personalized analysis of single-cell transcriptome sequencing data after organoid culture is performed. This describes the heterogeneity of tumor cells and the sensitivity of tumor cells to drugs after radiotherapy. It can accurately analyze the characteristics of various cell subpopulations in lung cancer brain metastases organoids and their roles in the tumor microenvironment, providing strong support for the study of the mechanism of lung cancer brain metastasis and precision medicine. Attached Figure Description

[0033] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0034] Figure 1 is a flowchart of a method for analyzing the subpopulations and functional characteristics of organoid cells in lung cancer brain metastases according to an embodiment of the present invention.

[0035] Figure 2 is a system framework diagram of an analysis system for organoid cell subpopulations and functional characteristics of lung cancer brain metastases according to an embodiment of the present invention.

[0036] Figure 3 shows the changes in cell copy number for each subpopulation in Example 1.

[0037] Figure 4 shows the copy number variation of cell subpopulations in Example 1.

[0038] Figure 5 shows the analysis of four cell subpopulations in Example 1.

[0039] Figure 6 shows the proportion of cells in Example 1.

[0040] Figure 7 shows the proportion of cells in Example 1.

[0041] Figure 8 is a differentiation score diagram of cell subpopulations in Example 1. Detailed Implementation

[0042] The technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only a part of the embodiments of the present invention, and not all of them. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative effort are within the scope of protection of the present invention.

[0043] In the following description, references are made to “some embodiments,” which describe a subset of all possible embodiments. However, it is understood that “some embodiments” may be the same subset or different subsets of all possible embodiments and may be combined with each other without conflict.

[0044] If the application documents contain similar descriptions such as "first / second", the following explanation shall be added: In the following description, the terms "first / second / third" are used only to distinguish similar objects and do not represent a specific order of objects. It is understood that "first / second / third" may be interchanged in a specific order or sequence where permitted, so that the embodiments of this application described herein can be implemented in an order other than that illustrated or described herein.

[0045] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this application belongs. The terminology used herein is for the purpose of describing embodiments of this application only and is not intended to limit this application.

[0046] Example 1

[0047] Figure 1 is a flowchart of a method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases according to an embodiment of the present invention. As shown in Figure 1, the method includes the following steps:

[0048] Step S100, data quality control: quality control is performed on the single-cell RNA sequencing data of organoids to remove low-quality data and ensure data reliability.

[0049] Specifically, in step S100, the single-cell transcriptome data is first read in the R environment and its overall condition is checked. The doubletFinder package is used to remove double cells, and samples with a mitochondrial ratio greater than 25% and a red blood cell ratio greater than 5% are screened out.

[0050] Step S200: Remove batch effects. Use a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency.

[0051] As shown in Figures 3 to 7, specifically, in this embodiment, dispersion analysis is first used to screen for highly variable genes, including:

[0052] Based on the coefficient of variation (CV) of gene expression, gene dispersion is calculated using Seurat's FindVariableFeatures tool to screen for genes with significant expression fluctuations. The method can employ VST (Variance Stabilizing Transformation) to fit the mean-variance relationship through local multinomial regression, suitable for complex datasets, or SCTransform to integrate a negative binomial regression model, simultaneously handling standardization and screening for highly variable genes, suitable for large-scale data. Finally, 2000-3000 highly variable genes are selected, preserving characteristics of significant biological differences.

[0053] Batch effect removal employs the Harmony method, including:

[0054] Data integration merges samples from different batches into a single Seurat object, preserving the original expression matrix.

[0055] Run Harmony, in the PCA dimensionality reduction space, and adjust batch differences by iterative clustering and linear correction factors, specifying grouping variables (such as sample origin).

[0056] Subsequent analysis used the Harmony-corrected embedding matrix for UMAP / t-SNE dimensionality reduction and clustering.

[0057] In another embodiment, the Seurat method can also be used for batch effect removal, including:

[0058] Anchor point identification uses CCA (canonical correlation analysis) for dimensionality reduction to find "anchor cells" (nearest neighbors) across batches in low-dimensional space; correction factor calculation is performed to construct an integrated model to correct batch effects based on gene expression differences of anchor cells; data fusion uses the corrected expression matrix for subsequent differential analysis, functional enrichment, etc.

[0059] By following the steps above, batch effects can be systematically eliminated, and true biological variations can be preserved, providing a reliable basis for subsequent differential expression and functional analysis.

[0060] Step S300, cell clustering: through dimensionality reduction and cluster analysis, cells are divided into different subpopulations to reveal their heterogeneity and diversity in the tumor microenvironment.

[0061] Specifically, in this embodiment, PCA is used to divide cell subpopulations. Through principal component selection and dimensionality reduction optimization and subpopulation biological annotation verification, differential genes of each subpopulation are calculated, and cell type-specific markers are screened.

[0062] Then, the malignant subpopulations of tumor cells were inferred using InferCNV. Based on the cell selection strategy, the cells were divided into a normal control group and an input data group. After tumor cell identification, the cells were reclassified into four subpopulations according to the markers of different cell subpopulations: low copy number tumor cells, stem cell-like tumor cells, stromal-like tumor cells, and neutrophil-like tumor cells. The proportion of each subpopulation in different samples was calculated.

[0063] Step S400, inferring copy number variations: By analyzing copy number variations in single-cell data, inferring genomic instability and possible carcinogenic features of cells.

[0064] Specifically, this step uses the monocle3 package to infer the differentiation trajectory of cells and finds that stem cell-like tumor cell populations differentiate into neutrophil-like and stromal-like tumor cell populations in multiple ways. At the same time, low copy number tumor cell populations have lower differentiation characteristics. The cytoTRACE2 package is used to further infer the differentiation potential of the four subpopulations.

[0065] Step S500: Using pseudo-time series analysis, reconstruct the cell development or transformation process to explore changes in cell fate during lung cancer brain metastasis.

[0066] Specifically, this step used the scMetabolism package to assess the metabolic characteristics of each cell subpopulation and visualized them using dot plots. The results showed that low copy number tumor cells exhibited active multiple metabolic pathways, such as the interconversion of pentoses and glucuronides, oxidative phosphorylation, and glycolysis; neutrophil-like tumor cells primarily focused on the interconversion of pentoses and glucuronides; stem cell-like tumor cells showed moderate metabolic activity in multiple pathways; and stromal-like tumor cells exhibited high signal intensity in pathways such as oxidative phosphorylation and glycolysis.

[0067] Step S600, functional enrichment analysis, identifies key pathways and molecular markers associated with lung cancer brain metastasis by functionally annotating different cell subpopulations.

[0068] Specifically, in this step, the pseudobulk package was used to compare differentially expressed genes in tumor cells before and after radiotherapy, identifying 12 significantly upregulated genes.

[0069] Genes were analyzed, and their expression changes were visualized using a volcano plot. Further analysis of the prognostic impact of these genes on adenocarcinoma patients in the TCGA database revealed that high expression of KRT17 and RAET1L was associated with a poorer prognosis in lung adenocarcinoma patients. Functional enrichment analysis of differentially upregulated genes primarily involved biological processes such as humoral immunity and lymphocyte chemotaxis. KEGG analysis showed that related pathways included cytokine-receptor interactions, lipid metabolism, and atherosclerosis, while GSEA analysis showed statistically significant differences in pathways such as drug metabolism—cytochrome P450 and phenylalanine metabolism.

[0070] Step S700: Drug sensitivity analysis before and after radiotherapy. This analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, providing a basis for individualized treatment plans.

[0071] Specifically, this step uses the oncoPredic package to predict the sensitivity of tumor cells to different drugs before and after radiotherapy, and finds that the IC50 values ​​of 12 drugs have significant differences, including the common lung cancer chemotherapy drug docetaxel. The differences in drug sensitivity of samples before and after radiotherapy are shown by box plots.

[0072] Example 2

[0073] On the other hand, the present invention also provides an analysis system for the subpopulations and functional characteristics of organoid cells in lung cancer brain metastases, comprising:

[0074] Data quality control module 1 performs quality control on organoid single-cell RNA sequencing data, removing low-quality data and ensuring data reliability;

[0075] Batch Effect Removal Module 2 employs a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency.

[0076] Cell clustering module 3, through dimensionality reduction and cluster analysis, divides cells into different subpopulations, revealing their heterogeneity and diversity within the tumor microenvironment.

[0077] The copy number variation inference module 4 infers genomic instability and possible carcinogenic features of cells by analyzing copy number variations in single-cell data.

[0078] Using the pseudo-time series analysis module 5, we reconstructed the cell development or transformation process and explored the changes in cell fate during lung cancer brain metastasis.

[0079] Functional enrichment analysis module 6 identifies key pathways and molecular markers associated with lung cancer brain metastasis by performing functional annotation on different cell subpopulations.

[0080] Module 7, which analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, provides a basis for individualized treatment plans.

[0081] Although embodiments of the present invention have been shown and described above, it is to be understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions, and variations to the above embodiments within the scope of the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the protection scope of the present invention.

Claims

1. A method for analyzing the subpopulations and functional characteristics of organoid cells from lung cancer brain metastases, characterized in that, include: Step S100: Data quality control. Perform quality control on the single-cell RNA sequencing data of organoids to remove low-quality data and ensure data reliability. Step S200: Remove batch effects. Use a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency. Step S300: Cell segmentation. Through dimensionality reduction and cluster analysis, cells are divided into different subpopulations, revealing their heterogeneity and diversity within the tumor microenvironment. Step S400, inferring copy number variations: By analyzing copy number variations in single-cell data, inferring genomic instability and possible carcinogenic features of cells; Step S500: Using pseudo-time series analysis, reconstruct the cell development or transformation process to explore changes in cell fate during lung cancer brain metastasis; Step S600, functional enrichment analysis, identifies key pathways and molecular markers associated with lung cancer brain metastasis by functional annotation of different cell subpopulations; Step S700: Drug sensitivity analysis before and after radiotherapy. This analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, providing a basis for individualized treatment plans.

2. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases as described in claim 1, characterized in that, In step S100, single-cell transcriptome data is read. The single-cell transcriptome data is read in the R environment and its overall condition is checked. Double cells are removed using the doubletFinder package, and samples with a mitochondrial ratio greater than 25% and a red blood cell ratio greater than 5% are screened out.

3. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases organoids as described in claim 2, characterized in that, In step S200, the Harmony or Seurat algorithm is used to screen for highly variable genes and remove batch effects.

4. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases organoids as described in claim 3, characterized in that, In step S300, cluster analysis was performed using PCA to separate 25 cell subpopulations, which were then visualized using UMAP. Subsequently, the expression of epithelial cell markers was combined, and tumor cells in organoids were inferred using the inferCNV method.

5. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases organoids as described in claim 4, characterized in that, In step S300, after tumor cell identification, the cells are reclassified into four subpopulations based on markers of different cell subpopulations: low copy number tumor cells, stem cell-like tumor cells, stromal-like tumor cells, and neutrophil-like tumor cells, and the proportion of each subpopulation in different samples is calculated.

6. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases as described in claim 5, characterized in that, In step S400, the monocle3 package is used to infer the differentiation trajectory of cells. It is found that stem cell-like tumor cell populations differentiate into neutrophil-like and stromal-like tumor cell populations in multiple ways. At the same time, low copy number tumor cell populations have lower differentiation characteristics. The cytoTRACE2 package is used to further infer the differentiation potential of the four subpopulations.

7. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases organoids as described in claim 6, characterized in that, In step S500, the metabolic characteristics of each cell subpopulation are assessed using the scMetabolism package and visualized using a dot plot, showing that low copy number tumor cells have multiple active metabolic pathways.

8. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases organoids as described in claim 7, characterized in that, In step S600, the pseudobulk package was used to compare differentially expressed genes in tumor cells before and after radiotherapy, identifying significantly upregulated genes. High expression of KRT17 and RAET1L was found to be associated with poorer prognosis in lung adenocarcinoma patients. Functional enrichment analysis of the differentially upregulated genes mainly involved biological processes such as humoral immunity and lymphocyte chemotaxis. KEGG analysis showed that related pathways included cytokine-receptor interactions, lipid metabolism, and atherosclerosis, while GSEA analysis showed statistically significant differences in drug metabolism pathways such as cytochrome P450 and phenylalanine metabolism.

9. The method for analyzing the cell subpopulations and functional characteristics of lung cancer brain metastases as described in claim 8, characterized in that, In step S700, the oncoPredic package is used to predict the sensitivity of tumor cells to different drugs before and after radiotherapy, including the significant difference in IC50 values ​​of the lung cancer chemotherapy drug docetaxel.

10. An analysis system for organoid cell subpopulations and functional characteristics in lung cancer brain metastases, characterized in that, include: Data quality control module 1 performs quality control on organoid single-cell RNA sequencing data, removing low-quality data and ensuring data reliability; Batch Effect Removal Module 2 employs a batch effect removal algorithm to eliminate technical deviations between batches and ensure data consistency. Cell clustering module 3, through dimensionality reduction and cluster analysis, divides cells into different subpopulations, revealing their heterogeneity and diversity within the tumor microenvironment. The copy number variation inference module 4 infers genomic instability and possible carcinogenic features of cells by analyzing copy number variations in single-cell data. Using the pseudo-time series analysis module 5, we reconstructed the cell development or transformation process and explored the changes in cell fate during lung cancer brain metastasis. Functional enrichment analysis module 6 identifies key pathways and molecular markers associated with lung cancer brain metastasis by performing functional annotation on different cell subpopulations. Module 7, which analyzes the differences in drug sensitivity among different cell subpopulations before and after radiotherapy, provides a basis for individualized treatment plans.